Skip to main content
Erschienen in: Journal of Hematology & Oncology 1/2011

Open Access 01.12.2011 | Letter to the Editor

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells

verfasst von: Mu Hao, Li Zhang, Gang An, Weiwei Sui, Zhen Yu, Dehui Zou, Yan Xu, Hong Chang, Lugui Qiu

Erschienen in: Journal of Hematology & Oncology | Ausgabe 1/2011

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of myeloma (MM) cells. This study identified that microRNA-15a and -16 expressions tightly correlated with proliferation and drug sensitivity of MM cells. miRNA-15a/-16 expression in MM cells was significantly increased after treatment with cytotoxic agents. The interaction of bone marrow stromal cells (BMSC) with MM cells resulted in decreased miRNA-15a/-16 expression and promoted the survival of the MM cells. Interleukin-6 (IL-6) produced by BMSCs suppressed the expression of miRNA-15a and 16 in a time- and dose- dependent pattern, with the suppression on miRNA-15a being more significant than on miRNA-16. miRNA-15a-transfected MM cells were found to be arrested in G1/S checkpoint, and the transfected MM cells had decreased growth and survival. In conclusion, our data suggest that via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1756-8722-4-37) contains supplementary material, which is available to authorized users.

Authors' contributions

MH provided the concept and design of the study, acquisition of data, analysis and interpretation of data, drafting the manuscript; L Zh and GA performed myeloma cell Stem-loop RT-PCR assay; WWS, DHZ collected samples from myeloma patients; ZY and YX assisted in data collection; HC and LGQ revised the manuscript and gave final approval of the version to be submitted. All authors have read and approved the final manuscript.
Abkürzungen
MM
multiple myeloma
BMSCs
bone marrow stromal cells
IL-6
interleukin 6
VEGF
Vascular-Endothelial Growth Factor
ELISA
enzyme-linked immunosorbent assay

To the Editor

Multiple myeloma (MM) is an incurable plasma cell malignancy [13]. Binding of MM cells to bone marrow stromal cells (BMSCs) promotes the growth, survival, metastasis and drug resistance of the MM cells. The molecular bases of MM progression and drug resistance remain incompletely understood [4, 5]. In this study, apoptosis analysis by flow cytometry showed that BMSCs protect U266 and NCI-H929 myeloma cells from apoptosis induced by melphalan and bortezomib. (Figure 1A). IL-6 and VEGF are critical growth factors for myeloma cells. Both are mainly produced by BMSCs [68]. By ELISA analysis, we found that the level of IL-6 and VEGF secreted in the supernatant of BMSCs derived from MM patient (MM-BMSCs) was significantly higher (188.8+9.4 pg/mL and 1497.2+39.7 pg/mL, respectively) than that of normal BMSCs (115.0+15.1 pg/mL and 1239.0+21.1 pg/mL, respectively; p < 0.05).
microRNA -15a and -16 are located on chromosome 13, an area commonly deleted in MM. Deletion of chromosome 13 predicts a significantly reduced survival in patient with MM [911]. We thus focused on the functions of miRNA-15a and -16. We found that miRNA-15a/-16 expression in MM cells was significantly increased under melphalan and bortezomib treatment (Figure 1B). Moreover, dexamethasone sensitive MM cell line, MM1S, expressed higher level of miRNA-15a than the resistant MM1R. miRNA-15a expression in MMIS and MM1R was 909.73 ± 7.12 and 134.88 ± 19.85 (p < 0.01), respectively, and miRNA-16 expression in those cells was 9.83 ± 2.01 and 9.20 ± 3.81 (p > 0.05), respectively. Interestingly, the interaction of MM cells with MM-BMSCs inhibited miRNA-15a and -16 expressions in MM cells. (Figure 1B) IL-6 secreted by MM-BMSCs decreased expression of miRNA-15a and -16 in myeloma cells in a time- and dose- dependent pattern. (Figure 1C,D) The suppression on miRNA-15a was more significant than on miRNA-16 in myeloma cells. Previous study has identified cyclinD1, cyclinD2 and CDC25A as the targets of miRNA-15a [12]. Our data further showed that miRNA-15a-transfected MM cells were arrested in G1/S checkpoint. The over-expression of miRNA-15a inhibited growth and survival of the transfected MM cells.
In conclusion, this study identified that microRNA-15a and -16 expressions correlated well with proliferation and drug sensitivity of MM cells. MM-BMSCs enhanced the survival of the MM cells and protected them from drug-induced apoptosis by suppressing miRNA-15a/-16 expression. IL-6 secreted by the MM-BMSCs plays a pivotal role in this process.

Conflicts of Interests

The authors declare that they have no competing interests.

Acknowledgements

This work was supported in part by grants from the National Natural Science Foundation of China (30871095 & 81172255). Tianjin Science and Technology Supporting Programme (09ZCGYSF01000) and Foundation for Youth Researcher of CAMS & PUMC.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors' contributions

MH provided the concept and design of the study, acquisition of data, analysis and interpretation of data, drafting the manuscript; L Zh and GA performed myeloma cell Stem-loop RT-PCR assay; WWS, DHZ collected samples from myeloma patients; ZY and YX assisted in data collection; HC and LGQ revised the manuscript and gave final approval of the version to be submitted. All authors have read and approved the final manuscript.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Anhänge

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.
Literatur
1.
Zurück zum Zitat Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348: 2609-2617. 10.1056/NEJMoa030288.CrossRefPubMed Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348: 2609-2617. 10.1056/NEJMoa030288.CrossRefPubMed
2.
Zurück zum Zitat Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC: Focus on multiple myeloma. Cancer Cell. 2004, 6: 439-444. 10.1016/j.ccr.2004.10.020.CrossRefPubMed Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC: Focus on multiple myeloma. Cancer Cell. 2004, 6: 439-444. 10.1016/j.ccr.2004.10.020.CrossRefPubMed
3.
Zurück zum Zitat Johann Micallef, Moyez Dharsee, Jian Chen, Suzanne Ackloo, Ken Evans, Luqui Qiu, Hong Chang: Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. Journal of Hematology & Oncology. 2010, 3: 13-10.1186/1756-8722-3-13.CrossRef Johann Micallef, Moyez Dharsee, Jian Chen, Suzanne Ackloo, Ken Evans, Luqui Qiu, Hong Chang: Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. Journal of Hematology & Oncology. 2010, 3: 13-10.1186/1756-8722-3-13.CrossRef
4.
Zurück zum Zitat Jiahuai Tan, Shundong Cang, Yuehua Ma, Petrillo Richard, Delong Liu: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology & Oncology. 2010, 3: 5-10.1186/1756-8722-3-5.CrossRef Jiahuai Tan, Shundong Cang, Yuehua Ma, Petrillo Richard, Delong Liu: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology & Oncology. 2010, 3: 5-10.1186/1756-8722-3-5.CrossRef
5.
Zurück zum Zitat Venumadhav Kotla, Swati Goel, Sangeeta Nischal, Christoph Heuck, Kumar Vivek, Bhaskar Das, Amit Verma: Mechanism of action of lenalidomide in hematological malignancies. Journal of Hematology & Oncology. 2009, 2: 36-10.1186/1756-8722-2-36.CrossRef Venumadhav Kotla, Swati Goel, Sangeeta Nischal, Christoph Heuck, Kumar Vivek, Bhaskar Das, Amit Verma: Mechanism of action of lenalidomide in hematological malignancies. Journal of Hematology & Oncology. 2009, 2: 36-10.1186/1756-8722-2-36.CrossRef
6.
Zurück zum Zitat Raab Marc, Klaus Podar, Iris Breitkreutz: Multiple myeloma. Lancet. 2009, 374: 324-339. 10.1016/S0140-6736(09)60221-X.CrossRefPubMed Raab Marc, Klaus Podar, Iris Breitkreutz: Multiple myeloma. Lancet. 2009, 374: 324-339. 10.1016/S0140-6736(09)60221-X.CrossRefPubMed
7.
Zurück zum Zitat Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994, 84: 3063-3070.PubMed Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994, 84: 3063-3070.PubMed
8.
Zurück zum Zitat Mahindra A, Hideshima T, Anderson KC: Multiple myeloma: biology of the disease. Blood Rev. 2010, 24 (Suppl 1): S5-11.CrossRefPubMed Mahindra A, Hideshima T, Anderson KC: Multiple myeloma: biology of the disease. Blood Rev. 2010, 24 (Suppl 1): S5-11.CrossRefPubMed
9.
Zurück zum Zitat Anuradha Budhu, Junfang Ji, Wang Xin: The clinical potential of microRNAs. Journal of Hematology & Oncology. 2010, 3: 37-10.1186/1756-8722-3-37.CrossRef Anuradha Budhu, Junfang Ji, Wang Xin: The clinical potential of microRNAs. Journal of Hematology & Oncology. 2010, 3: 37-10.1186/1756-8722-3-37.CrossRef
10.
Zurück zum Zitat Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009, 113: 6669-6680. 10.1182/blood-2009-01-198408.PubMedCentralCrossRefPubMed Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009, 113: 6669-6680. 10.1182/blood-2009-01-198408.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003, 101: 4569-4575. 10.1182/blood-2002-10-3017.CrossRefPubMed Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003, 101: 4569-4575. 10.1182/blood-2002-10-3017.CrossRefPubMed
12.
Zurück zum Zitat Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, Larusso N: microRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest. 2008, 118: 3714-3724. 10.1172/JCI34922.PubMedCentralCrossRefPubMed Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, Larusso N: microRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest. 2008, 118: 3714-3724. 10.1172/JCI34922.PubMedCentralCrossRefPubMed
Metadaten
Titel
Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
verfasst von
Mu Hao
Li Zhang
Gang An
Weiwei Sui
Zhen Yu
Dehui Zou
Yan Xu
Hong Chang
Lugui Qiu
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
Journal of Hematology & Oncology / Ausgabe 1/2011
Elektronische ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-4-37

Weitere Artikel der Ausgabe 1/2011

Journal of Hematology & Oncology 1/2011 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.